SetPoint Medical
- Industry
- Medical Equipment Manufacturing
- Founded Year
- 2007
- Headquarters
- Valencia, California, USA
- Employee Count
- 90
Key People
- Murthy V. Simhambhatla, Ph.D. - President and CEO
- David Chernoff - Chief Medical Officer
- Erik Styacich - Vice President of Sales
- Spencer Bailey - Vice President of Market Access & Reimbursement
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with successful backgrounds in the MedTech industry.
The presence of multiple successful MedTech entrepreneurs in the leadership team enhances the company's strategic direction and operational execution, increasing the likelihood of successful product development and commercialization.
- Clinical Need
-
Aspect: Very Strong
Summary: The company's focus on treating chronic autoimmune diseases addresses a significant unmet medical need.
Chronic autoimmune diseases like rheumatoid arthritis have limited treatment options, and SetPoint Medical's novel approach offers a potentially more effective and safer alternative, fulfilling a substantial clinical demand.
- Competition
-
Aspect: First mover
Summary: SetPoint Medical is pioneering in the field of bioelectronic medicine for autoimmune diseases.
As a first mover, the company has the advantage of establishing market presence but also faces the challenge of educating the market and overcoming initial adoption barriers without established benchmarks.
- Technical Challenge
-
Aspect: Complex
Summary: Developing implantable neuromodulation devices involves significant technical complexities.
The intricate nature of designing and manufacturing implantable devices that interface with the nervous system requires advanced engineering and rigorous testing, potentially leading to extended development cycles and increased costs.
- Patent
-
Aspect: Very Strong
Summary: The company holds a robust patent portfolio protecting its innovative technologies.
A comprehensive and strong patent portfolio safeguards the company's proprietary technologies, deterring competitors and enhancing the company's valuation and attractiveness to investors.
- Financing
-
Aspect: Well-funded
Summary: SetPoint Medical has secured substantial funding from reputable investors.
The significant capital raised enables the company to advance clinical trials, pursue regulatory approvals, and prepare for market entry, reducing financial constraints that could impede progress.
- Regulatory
-
Aspect: Pivotal Trial
Summary: The company is conducting pivotal trials to support regulatory approval.
Successfully completing pivotal trials is essential for obtaining regulatory approval, and the company's current focus on these trials indicates a commitment to meeting necessary regulatory standards for product commercialization.
Opportunity Rollup
- Odds of Success
- 3.15
- Peak Market Share
- 3.65
- Segment CAGR
- 9.1%
- Market Segment
- Neuromodulation Devices
- Market Sub Segment
- Implantable Devices for Autoimmune Diseases
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.18 |
| 2 | 0.55 |
| 3 | 1.28 |
| 4 | 2.56 |
| 5 | 3.65 |
Key Takeaway
SetPoint Medical is well-positioned in the emerging field of bioelectronic medicine, addressing significant unmet needs in autoimmune disease treatment with strong financial backing and a seasoned leadership team.